MX2019004766A - Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma. - Google Patents
Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma.Info
- Publication number
- MX2019004766A MX2019004766A MX2019004766A MX2019004766A MX2019004766A MX 2019004766 A MX2019004766 A MX 2019004766A MX 2019004766 A MX2019004766 A MX 2019004766A MX 2019004766 A MX2019004766 A MX 2019004766A MX 2019004766 A MX2019004766 A MX 2019004766A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- interferon
- gamma
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411783P | 2016-10-24 | 2016-10-24 | |
| PCT/IB2017/001427 WO2018078442A2 (en) | 2016-10-24 | 2017-10-24 | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019004766A true MX2019004766A (es) | 2019-09-27 |
Family
ID=60957345
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004766A MX2019004766A (es) | 2016-10-24 | 2017-10-24 | Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma. |
| MX2025012950A MX2025012950A (es) | 2016-10-24 | 2019-04-24 | Composiciones para usarse en el tratamiento de indicaciones relacionadas con interferon-gamma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025012950A MX2025012950A (es) | 2016-10-24 | 2019-04-24 | Composiciones para usarse en el tratamiento de indicaciones relacionadas con interferon-gamma |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3528845A2 (OSRAM) |
| JP (3) | JP2019532970A (OSRAM) |
| KR (2) | KR20240148970A (OSRAM) |
| CN (1) | CN110167593A (OSRAM) |
| AU (2) | AU2017352033A1 (OSRAM) |
| BR (1) | BR112019008156A2 (OSRAM) |
| CA (2) | CA3041434A1 (OSRAM) |
| EA (1) | EA201990930A1 (OSRAM) |
| IL (1) | IL266174B2 (OSRAM) |
| MX (2) | MX2019004766A (OSRAM) |
| SG (1) | SG11201903659WA (OSRAM) |
| WO (1) | WO2018078442A2 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016177913A1 (en) | 2015-05-07 | 2016-11-10 | Novimmune Sa | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| CN118165113B (zh) * | 2016-04-26 | 2025-10-28 | 恺兴生命科技(上海)有限公司 | 一种改善免疫应答细胞功能的方法 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2021185832A1 (en) | 2020-03-16 | 2021-09-23 | Swedish Orphan Biovitrum Ag | New therapeutic treatment |
| WO2021207150A1 (en) * | 2020-04-06 | 2021-10-14 | Celledit Llc | Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling |
| WO2024254401A1 (en) | 2023-06-09 | 2024-12-12 | Children's Hospital Medical Center | Treatment of stem cell graft failure |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| MXPA01005515A (es) * | 1998-12-01 | 2003-07-14 | Protein Design Labs Inc | Anticuerpos humanizados para gamma-interferon. |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| DK1848744T3 (da) * | 2005-01-27 | 2012-03-19 | Novimmune Sa | Humane anti-interferon-gamma-antistoffer og fremgangsmåder til anvendelse heraf |
| AU2006247039B2 (en) * | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| NZ585516A (en) | 2007-12-21 | 2012-07-27 | Hoffmann La Roche | Anti-cd20 antibody formulation |
| WO2013078378A1 (en) * | 2011-11-23 | 2013-05-30 | Amgen Inc. | Methods of treatment using an antibody against interferon gamma |
| KR20170018810A (ko) | 2014-06-10 | 2017-02-20 | 메이지 세이카 파루마 가부시키가이샤 | 안정한 아달리무맙 수성 제제 |
| WO2016177913A1 (en) * | 2015-05-07 | 2016-11-10 | Novimmune Sa | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
-
2017
- 2017-10-24 AU AU2017352033A patent/AU2017352033A1/en not_active Abandoned
- 2017-10-24 WO PCT/IB2017/001427 patent/WO2018078442A2/en not_active Ceased
- 2017-10-24 EP EP17829009.4A patent/EP3528845A2/en active Pending
- 2017-10-24 BR BR112019008156-9A patent/BR112019008156A2/pt unknown
- 2017-10-24 MX MX2019004766A patent/MX2019004766A/es unknown
- 2017-10-24 SG SG11201903659WA patent/SG11201903659WA/en unknown
- 2017-10-24 KR KR1020247033365A patent/KR20240148970A/ko not_active Ceased
- 2017-10-24 CA CA3041434A patent/CA3041434A1/en active Pending
- 2017-10-24 CN CN201780080221.6A patent/CN110167593A/zh active Pending
- 2017-10-24 KR KR1020197014837A patent/KR20190071785A/ko not_active Ceased
- 2017-10-24 CA CA3244670A patent/CA3244670A1/en active Pending
- 2017-10-24 JP JP2019521706A patent/JP2019532970A/ja not_active Withdrawn
- 2017-10-24 IL IL266174A patent/IL266174B2/en unknown
- 2017-10-24 EA EA201990930A patent/EA201990930A1/ru unknown
-
2019
- 2019-04-24 MX MX2025012950A patent/MX2025012950A/es unknown
-
2022
- 2022-10-28 JP JP2022173528A patent/JP7562074B2/ja active Active
-
2024
- 2024-09-06 JP JP2024153940A patent/JP2024170569A/ja active Pending
- 2024-11-12 AU AU2024264563A patent/AU2024264563A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3244670A1 (en) | 2025-11-29 |
| KR20240148970A (ko) | 2024-10-11 |
| WO2018078442A2 (en) | 2018-05-03 |
| JP7562074B2 (ja) | 2024-10-07 |
| AU2024264563A1 (en) | 2024-11-28 |
| IL266174B2 (en) | 2024-10-01 |
| MX2025012950A (es) | 2025-12-01 |
| EA201990930A1 (ru) | 2019-11-29 |
| CA3041434A1 (en) | 2018-05-03 |
| AU2017352033A1 (en) | 2019-06-06 |
| SG11201903659WA (en) | 2019-05-30 |
| KR20190071785A (ko) | 2019-06-24 |
| JP2024170569A (ja) | 2024-12-10 |
| BR112019008156A2 (pt) | 2019-07-02 |
| IL266174A (en) | 2019-06-30 |
| JP2019532970A (ja) | 2019-11-14 |
| WO2018078442A3 (en) | 2018-08-23 |
| EP3528845A2 (en) | 2019-08-28 |
| JP2022187025A (ja) | 2022-12-15 |
| IL266174B1 (en) | 2024-06-01 |
| CN110167593A (zh) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004766A (es) | Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma. | |
| ECSP20058592A (es) | Composiciones y métodos para tratar anemia | |
| MX2021012155A (es) | Composiciones y metodos para el tratamiento de la anemia. | |
| MX2019003938A (es) | Compuestos espirociclicos. | |
| BR112018073329A2 (pt) | combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase | |
| BR112018008103A2 (pt) | análogos de celastrol | |
| MX2021009899A (es) | Administracion y dosificacion de diaminofenotiazinas. | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| TW201713333A (en) | Methods of treating a neurodegenerative disease | |
| BR112019001039A2 (pt) | composição para uso no tratamento de transtorno depressivo maior | |
| MX2017012553A (es) | Compuestos espirociclicos. | |
| BR112017024163A2 (pt) | compostos bicíclicos | |
| EA201791933A1 (ru) | Ингибирование активности olig2 | |
| EA201691896A1 (ru) | Соединения и способы их применения | |
| BR112019006504A2 (pt) | regime de dosagem de avelumabe para o tratamento de câncer | |
| PH12017501897A1 (en) | 2-thiopyrimidinones | |
| MX2016014780A (es) | Metodos y composiciones de dasotralina para el tratamiento del adhd. | |
| MX2016014768A (es) | Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd. | |
| BR112017017594A2 (pt) | dosagens de panobinostat para mieloma múltiplo | |
| PH12018501570A1 (en) | Pharmaceutical composition for preventing or treating diabetic nephropathy | |
| HK40012444A (en) | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications | |
| BR112017006190A2 (pt) | agentes terapêuticos humanos | |
| EA201991517A1 (ru) | Композиции и способы ингибирования активности аргиназы |